To guide reasonably antival therapy in clinic and make therapic remedy, it is necessary for HBV-infected patients before or after antiviral therapy to detect HBV YMDD mutations.
HBV感染患者在治疗前后有必要检测是否存在HBV YMDD 变异株感染，为指导临床科学合理用药和制定治疗方案提供依据。
Conclusion the combination detection of YMDD variants, HBV DNA and HBV serum markers may define HBV reinfection after liver transplantation in the patients with hepatitis b.
结论乙型肝炎肝硬化患者肝移植后预防乙型肝炎复发应采用HBVDNA、YMDD变异及血清标志物联合检测。
To set up using the gene chip technology to detect and identify quickly and accurately the HBV P gene YMDD Motif mutation during the chronic hepatitis treated with lamivudine.
建立乙型肝炎病毒变异基因诊断芯片对拉米夫定治疗慢性乙型肝炎过程中出现的肝炎病毒P基因区YMDD变异进行快速准确的检测方法。
Methods Serum samples from 188 chronic hepatitis B patients with lamivudine therapy were collected and quantitatively tested with real-time PCR for HBV DNA and YMDD mutations.
方法将接受拉米夫定治疗的188例患者根据治疗时间进行分组，采用实时荧光PCR方法定量检测各组患者血清HBVDNA水平和酪氨酸-甲硫氨酸-天冬氨酸-天冬氨酸（YMDD）变异。
Conclusions During lamivudine therapy, there is no relation between the YMDD mutation and the HBV genotypes.
结论拉米夫定治疗期间，HBV的YMDD变异不受病毒基因型的影响。
Methods the serum YMDD mutation, HBV DNA, ALT and HbeAg levels of 60 patients on lamivudine therapy were detected by FQ-PCR, ELISA, and rate method, respectively.
方法采用实时荧光定量pcr、ELISA及速率法分别检测60例乙肝患者经拉米呋啶治疗后其血清YMDD、HBVDNA、乙肝标志物及alt的变化情况。
Methods the serum YMDD mutation, HBV DNA, ALT and HbeAg levels of 60 patients on lamivudine therapy were detected by FQ-PCR, ELISA, and rate method, respectively.
方法采用实时荧光定量pcr、ELISA及速率法分别检测60例乙肝患者经拉米呋啶治疗后其血清YMDD、HBVDNA、乙肝标志物及alt的变化情况。
应用推荐